This is to inform that due to some circumstances beyond the organizer control, "3rd Edition of International Precision Medicine Conference" (IPMC 2023) scheduled during April 24-26, 2023 in Orlando, Florida, USA has been postponed. The updated dates and venue will be displayed shortly.
Your registration can be transferred to the next edition, if you have already confirmed your participation at the event.
For further details, please contact us at [email protected] or call + 1 (702) 988 2320.
Theragnosis is a patient-management technique that combines diagnosis and treatment. Theragnosis integrates the domains of tumor diagnosis and therapy in oncology in order to improve upon existing procedures. The prospects for diagnosing disease, directing treatment, and monitoring outcomes bring up a new chapter in precision medicine. To develop efficient new targeted therapies with adequate benefit/risk to patients and a better molecular understanding of how to optimise drug selection, theragnostic encompasses a wide range of subjects, including personalised medicine, pharmacogenomics, and molecular imaging. The imaging agents and medications must be administered efficiently for successful theragnosis applications, resulting in appropriate imaging signal or drug concentration in the targeted disease location.
Title : Copper (II) complexes as potential anticancer agents
Salah S Massoud, University of Louisiana, United States
Title : Leveraging blockchain technology, edge computing and federated learning to enhance outcomes in precision medicine
Ingrid Vasiliu Feltes, MEDNAX, United States
Title : The new horizons in the patient- centered care for understanding of the reasons of its health problems – Psychosynthesis approach
Ewa Danuta Bialek, Institute of Psychosynthesis, Poland
Title : Hegazy theory for interpretation of human parthenogenesis: A new hypothesis
Abdelmonem Awad Hegazy, Zagazig University, Egypt
Title : Precision Oncology and Personalised Medicine: Innovative Technology for the Treatment of Colorectal Cancer
Huiqin Yang, ICON Clinical Research Ltd, United Kingdom
Title : The role of CD44v6 as a new immunotherapy target for urothelial cancer
Iris Adriana Maria Lodewijk, Institute of Biomedical Research, Spain